UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Receipt of Notice Re: Listing Bid Price Deficiency
On April 2, 2026, Evogene Ltd., or Evogene, issued a press release announcing its receipt of a letter from the Nasdaq
Stock Market LLC notifying Evogene of its deficiency in complying with Nasdaq Listing Rule 5550(a)(2) (which requires Evogene’s ordinary shares to maintain a closing bid price of at least $1.00 per share). A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
Exhibits
|
Exhibit
|
Description
|
Incorporation by Reference
The contents of the press release attached to this Report of Foreign Private Issuer on Form 6-K, or Form 6-K, as
Exhibit 99.1 are incorporated by reference in Evogene’s registration statements on Form F-3 (Securities and Exchange Commission, or SEC, File No.’s 333-277565 and 333-294650, and Form S-8 (SEC File No.’s. 333-193788, 333-201443, 333-203856,
333-259215, 333-286197 and 333-294648), and will be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: April 2, 2026 |
|
EVOGENE LTD.
(Registrant) By: /s/ Ofer Haviv Ofer Haviv Chief Executive Officer |